Developer docs
API playgroundTry for free, no card

Search company profiles

Open Source Imaging Consortium

Full company profile

uuid0027tpb

Namestring
Open Source Imaging Consortium
Legal namestring
Open Source Imaging Consortium, Inc.
Websiteurl
osicild.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Open Source Imaging Consortium (OSIC) is a global, 501(c)(3) nonprofit cooperative founded in May 2019 and headquartered in Holland, Michigan. The organization was created to advance research in interstitial lung diseases (ILDs) and rare fibrosing lung conditions by uniting academic institutions, pharmaceutical and biotechnology companies, medical imaging/AI vendors, and patient advocacy groups in pre-competitive collaboration. Its central asset is the OSIC Cloud Data Repository, the world's largest and most diverse ILD database, containing more than 20,789 anonymized HRCT scans with accompanying clinical data sourced from institutions across the US, EU, Asia, and Latin America — surpassing the consortium's original 15,000-scan goal.

The technology backbone is the OSIC Cloud, powered by VIDA Diagnostics, providing a secure, AI-ready, GDPR/HIPAA-compliant environment with automated pseudonymization, role-based access controls, multi-omic capability, and 13+ language support, governed under a U.S. Central IRB (Advarra) and multiple institutional IRBs. OSIC has developed and released open-source AI assets, notably CenTime (an event-conditional survival analysis model built with University College London), and runs scientific challenges (two Kaggle competitions engaging 2,500+ competitors) and working groups across data architecture, biomarkers, governance, and challenges. The platform's outputs underpin externally validated, FDA-cleared products such as 4DMedical's IQ-UIP and Coreline Soft's eFVC.

OSIC's business model is a membership consortium: 50+ institutional partners (including founding members Boehringer Ingelheim, Siemens Healthineers, CSL Behring, and FLUIDDA) commit multi-year funding and/or imaging and clinical data contributions in exchange for repository access, working-group participation, and collaborative research rights. Revenue is not publicly disclosed and the entity has no venture capital, private equity, or parent company ownership; governance sits with a Board of Directors, Core Science Leadership Team, and working-group structure. Go-to-market is community-led and event-driven, anchored by an annual member meeting (Amsterdam 2025, Barcelona 2026), peer-reviewed publication output (100+ publications), and thought-leadership content such as The Lung Lab podcast.

Short descriptiontext

OSIC is a global 501(c)(3) nonprofit cooperative operating the world's largest interstitial lung disease data repository (20,789+ anonymized HRCT scans), serving academic, pharmaceutical, medical imaging AI, and patient advocacy members through collaborative research and open-source AI tooling.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSaugatuck, United States
HQ citystring
Saugatuck
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging research, clinical data repository, lung disease biomarkers, AI imaging platform, nonprofit research consortium
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Imaging Research Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Institutional Membership Fees
TypeSubscription Recurring
Description

OSIC is a 501(c)(3) nonprofit that generates revenue through multi-year institutional membership commitments from academic, industry, and patient advocacy partners. Members receive access to the OSIC Cloud Data Repository, platform usage, and collaborative research resources.

osicild.org
2Collaborative Research Contributions
TypeManaged Services
Description

Partners contribute funding and/or pledge to contribute with imaging and clinical data to support OSIC operations. These multi-year commitments of funding support the consortium's mission to advance ILD research.

osicild.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1OSIC Cloud
Description

The OSIC Cloud Data Repository - a secure platform for managing de-identified, curated real-world and clinical trial data designed to fuel collaborative lung disease research.

osicild.org
+5 more records
Core offering1 text field

OSIC operates the OSIC Cloud Data Repository, the world's largest and most diverse anonymized HRCT imaging and clinical dataset for interstitial lung disease (ILD) research, comprising more than 20,789 committed scans from global academic and industry sources. Member institutions access this AI-ready, GDPR/HIPAA-compliant platform to train and validate imaging algorithms, develop digital biomarkers, and conduct collaborative research. Complementary offerings include the open-source CenTime survival-analysis model built with UCL, the longitudinal Project OPUS study, scientific working groups, and structured challenges (Kaggle and Imaging Consensus) that enable pre-competitive collaboration among academia, pharma, medical-imaging AI companies, and patient advocacy groups.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100+ peer-reviewed publications leveraging OSIC data
+2 more records
Product overview1 text field

Open Source Imaging Consortium (OSIC) is a global, 501(c)(3) nonprofit cooperative that operates a suite of interconnected products and initiatives focused on revolutionizing research in interstitial lung diseases (ILDs) and rare fibrosing lung conditions through digital imaging and machine learning. The core product is the OSIC Cloud Data Repository—the world's largest and most diverse ILD database with over 20,789 anonymized HRCT scans and accompanying clinical data. Supporting the repository is CenTime, an open-source survival analysis tool developed with UCL that demonstrates state-of-the-art performance in event-conditional modeling. Project OPUS provides a longitudinal study framework for consented ILD patients. Additional offerings include The Lung Lab podcast, Kaggle challenges for algorithm development, and upcoming initiatives including the Imaging Consensus Initiative and PCCT Readiness Initiative (both launching in 2026). The organization also facilitates peer-to-peer collaboration through five Working Groups focused on data architecture, curation, challenges, governance, and biomarkers. All digital biomarkers and algorithms developed are released open source for the benefit of patients worldwide.

Product and service5 records
1OSIC Cloud Data Repository
CategoryCloud Data Platform
Description

Secure, AI-ready platform housing the world's largest and most diverse global database of anonymized HRCT scans with accompanying clinical data for interstitial lung disease research, accessible to OSIC member institutions for algorithm training, biomarker discovery, and trial endpoint refinement.

2CenTime
CategoryAI/ML Software
Description

Open-source survival analysis model that directly estimates time-to-event occurrence for disease progression prediction in respiratory health, using an event-conditional censoring mechanism and performing robustly even with limited uncensored data.

3Project OPUS (OSIC Pulmonary Understanding Study)
CategoryResearch Program
Description

Longitudinal study framework capturing prospective, multi-omic clinical and imaging data from consented ILD patients worldwide, aligned to modern research needs and feeding the OSIC Cloud Data Repository.

4Imaging Consensus Initiative
CategoryResearch Initiative
Description

Scientific challenge launching in 2026 designed to characterize agreement and divergence among imaging AI algorithms across fibrotic lung disease, enabling the field to map consensus and uncertainty.

5PCCT Readiness Initiative
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership30 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

Project Cairn collaboration to create a Rare Lung Disease Intelligence Engine by integrating global imaging data, clinical information, and phenotype within a secure compute environment. Combines OSIC's globally harmonized dataset with infrastructure from the Baillie Gifford Pandemic Science Hub, enabling large-scale integrated analysis across imaging, clinical, and biological data.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2022-12-13
Description

Partnership to help continue adding anonymized, comprehensive data sets to the OSIC Data Repository, expanding the diversity and scale of available clinical data.

3Boehringer Ingelheim
Strategic tierFoundingTypeStrategic or Co-development Partner
Description

Founding pharmaceutical partner of OSIC. One of the world's leading research-driven pharmaceutical companies contributing to the consortium's mission to advance ILD research.

osicild.org
Strategic tierFoundingTypeStrategic or Co-development Partner
Description

Founding industry partner, one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, and health IT.

Strategic tierFoundingTypeStrategic or Co-development Partner
Description

Founding biotechnology partner, one of the world's largest driven by its promise to help patients lead full lives with therapies for coagulation disorders, primary immune deficiencies, and respiratory diseases.

Strategic tierFoundingTypeStrategic or Co-development Partner
Description

Founding partner and world leader in Functional Respiratory Imaging (FRI) research and development, providing respiratory solutions for better patient care.

Strategic tierCoreTypeTechnology or Integration
Description

Platform partner powering the OSIC Cloud, a secure platform for managing de-identified, curated real-world and clinical trial data designed to fuel collaborative lung disease research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key academic partner providing computational science leadership (Prof. David Barber) and radiology leadership (Prof. Joseph Jacob). Collaborator on CenTime development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key academic partner providing pulmonology leadership (Dr. Kevin Brown). Major contributor of patient data and research expertise.

10University of California, San Diego
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner providing US radiology leadership (Dr. Jonathan Chung). Collaborates on ILD research and imaging biomarker development.

osicild.org
Strategic tierKeyTypeTechnology or Integration
Description

Medical imaging technology partner specializing in quantitative analysis for ILD research and lung disease imaging.

12Coreline Soft
Strategic tierKeyTypeTechnology or Integration
Description

Medical AI imaging partner that developed estimated FVC (eFVC) using OSIC data. First Korean medical AI company with ISO/IEC AI 24001 certification and FDA 510(k) clearance.

osicild.org
Strategic tierKeyTypeTechnology or Integration
Description

Medical technology partner with FDA-cleared IQ-UIP software developed using OSIC data. Contributed to regulatory activities and development of AI imaging solutions.

Strategic tierKeyTypeTechnology or Integration
Description

AI-powered imaging biomarkers partner developing e-ILD software for ILD assessment, using OSIC Data Repository for refinement and validation.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Patient advocacy partner helping ensure patient perspectives are central to research priorities and that advances benefit patients directly.

16European Pulmonary Fibrosis Federation (EU-PFF)
Strategic tierKeyTypeStrategic or Co-development Partner
Description

European patient advocacy organization working to improve outcomes for people with pulmonary fibrosis.

osicild.org
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Patient advocacy organization providing patient and caregiver perspectives to guide research direction.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

UK-based patient advocacy organization dedicated to finding answers and providing support for those affected by pulmonary fibrosis.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Leading international nonprofit dedicated to finding a cure for sarcoidosis and improving care through research, education, and support.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Collaborative partner in the CPA-1 program bringing gene editing innovation and global lung imaging data resources to advance therapies for alpha-1 antitrypsin deficiency.

Strategic tierGeneralTypeTechnology or Integration
Description

AI imaging partner that analyzed data from OSIC Cloud lung cancer screening/ILA cohort to identify proof of concept for AI risk scoring.

22Medical University of Vienna
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Key academic partner providing radiology expertise and research contributions to ILD imaging biomarker development.

osicild.org
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Major academic contributor that has contributed more than 1,000 anonymized patient cases to the OSIC Cloud Data Repository.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Biotechnology partner contributing to the consortium's pharmaceutical and research collaborations in respiratory disease.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Biopharmaceutical partner contributing to collaborative research efforts in fibrotic lung diseases.

26GMV
Strategic tierGeneralTypeTechnology or Integration
Description

Technology partner using OSIC data repository in its SEPI-IA research initiative developing AI tools for medical imaging of rare respiratory diseases.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Major academic medical center contributing to the consortium's research network and data sharing efforts.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key academic partner providing radiology leadership expertise for ILD research and AI biomarker development.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Medical imaging partner funding Project OPUS to explore potential of X-ray imaging for earlier diagnosis and disease management of IPF.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Global online competition platform hosting OSIC's Pulmonary Fibrosis Progression Challenges with over 5 million registered users from 250 countries.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Iowa-based lung imaging AI company that powers the OSIC Cloud platform. Provides the underlying infrastructure for OSIC's data repository and develops its own quantitative lung imaging products.

TypeDirect peer
Description

Vienna-based AI radiology company that used OSIC Cloud data to develop its ILA/ILD risk scoring proof of concept. Operates in the same imaging AI category serving similar pharma and clinical customers.

TypeDirect peer
Description

UK-based AI imaging company developing e-ILD for ILD assessment using OSIC's anonymized HRCT repository. Brainomix's CMIO also chairs the OSIC Board, evidencing deep two-way collaboration.

4Coreline Soft
TypeDirect peer
Description

Korean medical AI company that developed the eFVC quantitative imaging metric using OSIC data as its primary training set. First Korean firm with ISO/IEC AI 24001 certification and FDA 510(k) clearance for chest CT AI.

TypeEmerging player
Description

Spain-based AI radiology platform company with whole-body imaging AI capabilities that overlap with OSIC's pulmonary focus. Builds regulatory-grade imaging biomarkers for pharma sponsors.

TypeBroad incumbent
Description

Global medical imaging incumbent and OSIC founding industry partner. Offers competing AI-Rad Companion chest CT capabilities at scale but as part of a broader imaging portfolio rather than an ILD-specialized focus.

TypeDirect peer
Description

Belgian functional respiratory imaging company and OSIC founding partner. Develops FRI-based biomarkers for respiratory drug development, serving the same pharma customer base for ILD trial endpoints.

TypeOthers
Description

Public-private partnership that operates the CPA-1 program with OSIC for alpha-1 antitrypsin deficiency. Functions as an adjacent consortium/regulatory-science enabler rather than a direct AI imaging competitor.

TypeDirect peer
Description

Australia-listed lung imaging AI company whose FDA-cleared IQ-UIP software for UIP detection was developed using the OSIC data repository. Directly consumes OSIC data and develops competing/complementary ILD AI products.

TypeDirect peer
Description

Dutch quantitative lung imaging company specializing in CT-based analysis for ILD and other lung diseases. Listed OSIC technology partner with overlapping product/customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Open Source Imaging Consortium

Medical Imaging Research Platformosicild.org

OSIC is a global 501(c)(3) nonprofit cooperative operating the world's largest interstitial lung disease data repository (20,789+ anonymized HRCT scans), serving academic, pharmaceutical, medical imaging AI, and patient advocacy members through collaborative research and open-source AI tooling.

What Open Source Imaging Consortium does

Open Source Imaging Consortium (OSIC) is a global, 501(c)(3) nonprofit cooperative founded in May 2019 and headquartered in Holland, Michigan. The organization was created to advance research in interstitial lung diseases (ILDs) and rare fibrosing lung conditions by uniting academic institutions, pharmaceutical and biotechnology companies, medical imaging/AI vendors, and patient advocacy groups in pre-competitive collaboration. Its central asset is the OSIC Cloud Data Repository, the world's largest and most diverse ILD database, containing more than 20,789 anonymized HRCT scans with accompanying clinical data sourced from institutions across the US, EU, Asia, and Latin America — surpassing the consortium's original 15,000-scan goal.

The technology backbone is the OSIC Cloud, powered by VIDA Diagnostics, providing a secure, AI-ready, GDPR/HIPAA-compliant environment with automated pseudonymization, role-based access controls, multi-omic capability, and 13+ language support, governed under a U.S. Central IRB (Advarra) and multiple institutional IRBs. OSIC has developed and released open-source AI assets, notably CenTime (an event-conditional survival analysis model built with University College London), and runs scientific challenges (two Kaggle competitions engaging 2,500+ competitors) and working groups across data architecture, biomarkers, governance, and challenges. The platform's outputs underpin externally validated, FDA-cleared products such as 4DMedical's IQ-UIP and Coreline Soft's eFVC.

OSIC's business model is a membership consortium: 50+ institutional partners (including founding members Boehringer Ingelheim, Siemens Healthineers, CSL Behring, and FLUIDDA) commit multi-year funding and/or imaging and clinical data contributions in exchange for repository access, working-group participation, and collaborative research rights. Revenue is not publicly disclosed and the entity has no venture capital, private equity, or parent company ownership; governance sits with a Board of Directors, Core Science Leadership Team, and working-group structure. Go-to-market is community-led and event-driven, anchored by an annual member meeting (Amsterdam 2025, Barcelona 2026), peer-reviewed publication output (100+ publications), and thought-leadership content such as The Lung Lab podcast.

Open Source Imaging Consortium firmographics

Firmographics
Name
Open Source Imaging Consortium
Legal name
Open Source Imaging Consortium, Inc.
Website
https://osicild.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
OSIC is a global 501(c)(3) nonprofit cooperative operating the world's largest interstitial lung disease data repository (20,789+ anonymized HRCT scans), serving academic, pharmaceutical, medical imaging AI, and patient advocacy members through collaborative research and open-source AI tooling.
Ownership category
akta.pro rank

Open Source Imaging Consortium industry classification

Industry
Product category
Medical Imaging Research Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Medical imaging research
  • Clinical data repository
  • Lung disease biomarkers
  • AI imaging platform
  • Nonprofit research consortium

Where Open Source Imaging Consortium is headquartered

Location

Headquarters

HQ city
Saugatuck
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Open Source Imaging Consortium business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Institutional Membership Fees: OSIC is a 501(c)(3) nonprofit that generates revenue through multi-year institutional membership commitments from academic, industry, and patient advocacy partners. Members receive access to the OSIC Cloud Data Repository, platform usage, and collaborative research resources.
  2. Collaborative Research Contributions: Partners contribute funding and/or pledge to contribute with imaging and clinical data to support OSIC operations. These multi-year commitments of funding support the consortium's mission to advance ILD research.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Open Source Imaging Consortium product offering

Product offering

Core offering

OSIC operates the OSIC Cloud Data Repository, the world's largest and most diverse anonymized HRCT imaging and clinical dataset for interstitial lung disease (ILD) research, comprising more than 20,789 committed scans from global academic and industry sources. Member institutions access this AI-ready, GDPR/HIPAA-compliant platform to train and validate imaging algorithms, develop digital biomarkers, and conduct collaborative research. Complementary offerings include the open-source CenTime survival-analysis model built with UCL, the longitudinal Project OPUS study, scientific working groups, and structured challenges (Kaggle and Imaging Consensus) that enable pre-competitive collaboration among academia, pharma, medical-imaging AI companies, and patient advocacy groups.

Product overview

Open Source Imaging Consortium (OSIC) is a global, 501(c)(3) nonprofit cooperative that operates a suite of interconnected products and initiatives focused on revolutionizing research in interstitial lung diseases (ILDs) and rare fibrosing lung conditions through digital imaging and machine learning. The core product is the OSIC Cloud Data Repository—the world's largest and most diverse ILD database with over 20,789 anonymized HRCT scans and accompanying clinical data. Supporting the repository is CenTime, an open-source survival analysis tool developed with UCL that demonstrates state-of-the-art performance in event-conditional modeling. Project OPUS provides a longitudinal study framework for consented ILD patients. Additional offerings include The Lung Lab podcast, Kaggle challenges for algorithm development, and upcoming initiatives including the Imaging Consensus Initiative and PCCT Readiness Initiative (both launching in 2026). The organization also facilitates peer-to-peer collaboration through five Working Groups focused on data architecture, curation, challenges, governance, and biomarkers. All digital biomarkers and algorithms developed are released open source for the benefit of patients worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • OSIC Cloud: The OSIC Cloud Data Repository - a secure platform for managing de-identified, curated real-world and clinical trial data designed to fuel collaborative lung disease research.
  • CenTime
  • Project OPUS
  • Imaging Consensus Initiative
  • PCCT Readiness Initiative
  • The Lung Lab

Products and services

  • OSIC Cloud Data Repository Secure, AI-ready platform housing the world's largest and most diverse global database of anonymized HRCT scans with accompanying clinical data for interstitial lung disease research, accessible to OSIC member institutions for algorithm training, biomarker discovery, and trial endpoint refinement.
  • CenTime Open-source survival analysis model that directly estimates time-to-event occurrence for disease progression prediction in respiratory health, using an event-conditional censoring mechanism and performing robustly even with limited uncensored data.
  • Project OPUS (OSIC Pulmonary Understanding Study) Longitudinal study framework capturing prospective, multi-omic clinical and imaging data from consented ILD patients worldwide, aligned to modern research needs and feeding the OSIC Cloud Data Repository.
  • Imaging Consensus Initiative Scientific challenge launching in 2026 designed to characterize agreement and divergence among imaging AI algorithms across fibrotic lung disease, enabling the field to map consensus and uncertainty.
  • PCCT Readiness Initiative

Quantifiable outcome

  • 100+ peer-reviewed publications leveraging OSIC data
  • +2 more outcomes

Companies that use Open Source Imaging Consortium

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Open Source Imaging Consortium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Open Source Imaging Consortium partnerships and signals

Strategic signal

Partnerships

30 partnerships are on record, tiered core, key, founding and general.

  • Baillie Gifford Pandemic Science Hub at University of EdinburghcoreStrategic or Co-development Partner · 21 May 2026Project Cairn collaboration to create a Rare Lung Disease Intelligence Engine by integrating global imaging data, clinical information, and phenotype within a secure compute environment. Combines OSIC's globally harmonized dataset with infrastructure from the Baillie Gifford Pandemic Science Hub, enabling large-scale integrated analysis across imaging, clinical, and biological data.
  • Medicom TechnologieskeyTechnology or Integration · 13 December 2022Partnership to help continue adding anonymized, comprehensive data sets to the OSIC Data Repository, expanding the diversity and scale of available clinical data.
  • Boehringer IngelheimfoundingStrategic or Co-development PartnerFounding pharmaceutical partner of OSIC. One of the world's leading research-driven pharmaceutical companies contributing to the consortium's mission to advance ILD research.
  • Siemens HealthineersfoundingStrategic or Co-development PartnerFounding industry partner, one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, and health IT.
  • CSL BehringfoundingStrategic or Co-development PartnerFounding biotechnology partner, one of the world's largest driven by its promise to help patients lead full lives with therapies for coagulation disorders, primary immune deficiencies, and respiratory diseases.
  • FLUIDDAfoundingStrategic or Co-development PartnerFounding partner and world leader in Functional Respiratory Imaging (FRI) research and development, providing respiratory solutions for better patient care.
  • VIDA DiagnosticscoreTechnology or IntegrationPlatform partner powering the OSIC Cloud, a secure platform for managing de-identified, curated real-world and clinical trial data designed to fuel collaborative lung disease research.
  • University College London (UCL)coreStrategic or Co-development PartnerKey academic partner providing computational science leadership (Prof. David Barber) and radiology leadership (Prof. Joseph Jacob). Collaborator on CenTime development.
  • National Jewish HealthcoreStrategic or Co-development PartnerKey academic partner providing pulmonology leadership (Dr. Kevin Brown). Major contributor of patient data and research expertise.
  • University of California, San DiegocoreStrategic or Co-development PartnerAcademic partner providing US radiology leadership (Dr. Jonathan Chung). Collaborates on ILD research and imaging biomarker development.
  • ThironakeyTechnology or IntegrationMedical imaging technology partner specializing in quantitative analysis for ILD research and lung disease imaging.
  • Coreline SoftkeyTechnology or IntegrationMedical AI imaging partner that developed estimated FVC (eFVC) using OSIC data. First Korean medical AI company with ISO/IEC AI 24001 certification and FDA 510(k) clearance.
  • 4DMedicalkeyTechnology or IntegrationMedical technology partner with FDA-cleared IQ-UIP software developed using OSIC data. Contributed to regulatory activities and development of AI imaging solutions.
  • BrainomixkeyTechnology or IntegrationAI-powered imaging biomarkers partner developing e-ILD software for ILD assessment, using OSIC Data Repository for refinement and validation.
  • American Lung AssociationkeyStrategic or Co-development PartnerPatient advocacy partner helping ensure patient perspectives are central to research priorities and that advances benefit patients directly.
  • European Pulmonary Fibrosis Federation (EU-PFF)keyStrategic or Co-development PartnerEuropean patient advocacy organization working to improve outcomes for people with pulmonary fibrosis.
  • PF WarriorskeyStrategic or Co-development PartnerPatient advocacy organization providing patient and caregiver perspectives to guide research direction.
  • Action for Pulmonary FibrosiskeyStrategic or Co-development PartnerUK-based patient advocacy organization dedicated to finding answers and providing support for those affected by pulmonary fibrosis.
  • Foundation for Sarcoidosis Research (FSR)keyStrategic or Co-development PartnerLeading international nonprofit dedicated to finding a cure for sarcoidosis and improving care through research, education, and support.
  • Critical Path Institute (C-Path)keyStrategic or Co-development PartnerCollaborative partner in the CPA-1 program bringing gene editing innovation and global lung imaging data resources to advance therapies for alpha-1 antitrypsin deficiency.
  • contextflowgeneralTechnology or IntegrationAI imaging partner that analyzed data from OSIC Cloud lung cancer screening/ILA cohort to identify proof of concept for AI risk scoring.
  • Medical University of ViennakeyStrategic or Co-development PartnerKey academic partner providing radiology expertise and research contributions to ILD imaging biomarker development.
  • University of FloridakeyStrategic or Co-development PartnerMajor academic contributor that has contributed more than 1,000 anonymized patient cases to the OSIC Cloud Data Repository.
  • GenentechkeyStrategic or Co-development PartnerBiotechnology partner contributing to the consortium's pharmaceutical and research collaborations in respiratory disease.
  • GalapagoskeyStrategic or Co-development PartnerBiopharmaceutical partner contributing to collaborative research efforts in fibrotic lung diseases.
  • GMVgeneralTechnology or IntegrationTechnology partner using OSIC data repository in its SEPI-IA research initiative developing AI tools for medical imaging of rare respiratory diseases.
  • Stanford MedicinekeyStrategic or Co-development PartnerMajor academic medical center contributing to the consortium's research network and data sharing efforts.
  • Imperial College London (National Heart and Lung Institute)coreStrategic or Co-development PartnerKey academic partner providing radiology leadership expertise for ILD research and AI biomarker development.
  • Carestream HealthkeyStrategic or Co-development PartnerMedical imaging partner funding Project OPUS to explore potential of X-ray imaging for earlier diagnosis and disease management of IPF.
  • KagglekeyStrategic or Co-development PartnerGlobal online competition platform hosting OSIC's Pulmonary Fibrosis Progression Challenges with over 5 million registered users from 250 countries.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Open Source Imaging Consortium competitors and assessment

Company assessment

Direct peers

  • VIDA Diagnostics: Iowa-based lung imaging AI company that powers the OSIC Cloud platform. Provides the underlying infrastructure for OSIC's data repository and develops its own quantitative lung imaging products.
  • contextflow: Vienna-based AI radiology company that used OSIC Cloud data to develop its ILA/ILD risk scoring proof of concept. Operates in the same imaging AI category serving similar pharma and clinical customers.
  • Brainomix: UK-based AI imaging company developing e-ILD for ILD assessment using OSIC's anonymized HRCT repository. Brainomix's CMIO also chairs the OSIC Board, evidencing deep two-way collaboration.
  • Coreline Soft: Korean medical AI company that developed the eFVC quantitative imaging metric using OSIC data as its primary training set. First Korean firm with ISO/IEC AI 24001 certification and FDA 510(k) clearance for chest CT AI.
  • FLUIDDA: Belgian functional respiratory imaging company and OSIC founding partner. Develops FRI-based biomarkers for respiratory drug development, serving the same pharma customer base for ILD trial endpoints.
  • 4DMedical: Australia-listed lung imaging AI company whose FDA-cleared IQ-UIP software for UIP detection was developed using the OSIC data repository. Directly consumes OSIC data and develops competing/complementary ILD AI products.
  • Thirona: Dutch quantitative lung imaging company specializing in CT-based analysis for ILD and other lung diseases. Listed OSIC technology partner with overlapping product/customer base.

Emerging players

  • Quibim: Spain-based AI radiology platform company with whole-body imaging AI capabilities that overlap with OSIC's pulmonary focus. Builds regulatory-grade imaging biomarkers for pharma sponsors.

Broad incumbents

  • Siemens Healthineers: Global medical imaging incumbent and OSIC founding industry partner. Offers competing AI-Rad Companion chest CT capabilities at scale but as part of a broader imaging portfolio rather than an ILD-specialized focus.

Others

  • Critical Path Institute: Public-private partnership that operates the CPA-1 program with OSIC for alpha-1 antitrypsin deficiency. Functions as an adjacent consortium/regulatory-science enabler rather than a direct AI imaging competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Open Source Imaging Consortium social profiles

Digital presence

Open Source Imaging Consortium compliance and trust

Trust signal

Compliance3 records

Open Source Imaging Consortium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Open Source Imaging Consortium leadership team

Management profile

Number of profiles

Profiles18 records

Open Source Imaging Consortium funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Open Source Imaging Consortium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Open Source Imaging Consortium

What does Open Source Imaging Consortium do?

OSIC operates the OSIC Cloud Data Repository, the world's largest and most diverse anonymized HRCT imaging and clinical dataset for interstitial lung disease (ILD) research, comprising more than 20,789 committed scans from global academic and industry sources. Member institutions access this AI-ready, GDPR/HIPAA-compliant platform to train and validate imaging algorithms, develop digital biomarkers, and conduct collaborative research. Complementary offerings include the open-source CenTime survival-analysis model built with UCL, the longitudinal Project OPUS study, scientific working groups, and structured challenges (Kaggle and Imaging Consensus) that enable pre-competitive collaboration among academia, pharma, medical-imaging AI companies, and patient advocacy groups.

Is Open Source Imaging Consortium a public or private company?

Open Source Imaging Consortium is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Open Source Imaging Consortium founded?

Open Source Imaging Consortium was founded in 2019. It employs 1 to 10 people.

Where is Open Source Imaging Consortium based?

Open Source Imaging Consortium is headquartered in Saugatuck, United States, in the North America region.

How does Open Source Imaging Consortium make money?

Two revenue lines are on record. Institutional Membership Fees are the primary driver. The others are collaborative Research Contributions.

Who are Open Source Imaging Consortium's main competitors?

Direct peers on record are VIDA Diagnostics, contextflow, Brainomix, Coreline Soft, FLUIDDA, 4DMedical and Thirona. Quibim is listed as an emerging player. Siemens Healthineers is listed as a broad incumbent. Critical Path Institute is listed as an others.

Does Open Source Imaging Consortium have an API?

No public API is recorded for Open Source Imaging Consortium.

What industry is Open Source Imaging Consortium in?

Open Source Imaging Consortium's product category is Medical Imaging Research Platform. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMedicom Helps Source Anonymized Clinical Information for OSIC Data Repository to Further Advance Research and Treatment for Interstitial Lung DiseasesMedicom Technologies has partnered with the Open Source Imaging Consortium (OSIC) to expand access to anonymized clinical data for research into interstitial lung diseases, leveraging Medicom's deepMed platform to source and de-identify medical images. The OSIC Data Repository, launched in 2021, is the world's largest ILD database with over 16,000 anonymized HRCT scans and accompanying clinical data. The organizations plan to expand their research, machine learning, and AI initiatives in 2023, with a focus on rare and cancerous diseases and improving care access for the Veteran Care Community.PR NewswireRepositório de dados global inédito para doenças pulmonares intersticiais é lançado por meio de colaboração acadêmica e industrialThe Open Source Imaging Consortium (OSIC) launched a global repository of anonymized CT scans and clinical data for interstitial lung diseases, currently holding 1,500 scans with a goal of reaching 15,000 by early 2022. This collaborative effort involves academics, patient groups, and industry partners aiming to advance open-source AI algorithms for improved diagnosis and treatment prediction. The dataset has been reviewed for privacy compliance and is available to OSIC members for scientific research.PR NewswireFirst-of-its-Kind, Global Data Repository for Interstitial Lung Diseases Launches Through Academic and Industry CollaborativeThe Open Source Imaging Consortium (OSIC) announced the launch of its first-of-its-kind global database containing anonymized HRCT scans and clinical data for interstitial lung diseases (ILDs), currently housing nearly 1,500 scans with a goal of reaching 15,000 by Q1 2022. The database was developed through a nearly three-year collaboration among radiologists, clinicians, computational scientists, and industry competitors, aiming to advance AI-based digital imaging biomarkers for diagnosis, prognosis, and treatment prediction of rare fibrotic lung diseases, with all resulting algorithms to be released as open source. OSIC is actively seeking additional scans from governmental agencies, patient advocacy groups, and through direct patient outreach to expand the repository.PR NewswireOpen Source Imaging Consortium (OSIC) Announces Winners of its $55,000 Kaggle ChallengeThe Open Source Imaging Consortium (OSIC) announced the winners of its $55,000 OSIC Pulmonary Fibrosis Progression Challenge, a machine learning competition administered by Kaggle to predict lung function decline in interstitial lung disease patients. First place went to Artyom Kulakov (Russia), second to Yusuke Ikemoto (Japan), and third to Khang Pham (Japan), selected from nearly 40,000 entries submitted by over 2,500 global competitors. OSIC, a global not-for-profit collaborative effort focused on advancing research into idiopathic pulmonary fibrosis—a disease with no known cause or cure—indicated it will host a second challenge in 2021 to continue this work.PR NewswireInterstitial Lung Disease (ILD) Experts And Advocates Announce Formation Of Open Source Imaging Consortium (OSIC)An international consortium of experts and advocates announced on May 22, 2019 the formation of the Open Source Imaging Consortium (OSIC), a global not-for-profit organization dedicated to advancing detection and diagnosis of interstitial lung diseases through digital imaging and machine learning. The consortium's founding partners include Boehringer Ingelheim, Siemens Healthineers, CSL Behring, and FLUIDDA, which will collaborate with academic institutions to build a repository of approximately 15,000 anonymized image scans and develop algorithms for commercial diagnostic tools. The initiative aims to reduce the current diagnostic timeline of up to two years by enabling pre-competitive collaboration between pharmaceutical companies, medical technology vendors, and academic institutions for patient benefit.